Profile data is unavailable for this security.
About the company
Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
- Revenue in CHF (TTM)15.16m
- Net income in CHF-11.14m
- Incorporated1995
- Employees64.00
- LocationKuros Biosciences AGWagistrasse 25SCHLIEREN 8952SwitzerlandCHE
- Phone+41 447334747
- Fax+41 447334740
- Websitehttp://www.kuros.ch/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Addex Therapeutics Ltd | 1.25m | -21.42m | 13.49m | 28.00 | -- | 0.9212 | -- | 10.82 | -0.5532 | -0.5532 | 0.0316 | 0.1496 | 0.0823 | -- | 4.60 | 44,546.79 | -141.40 | -43.18 | -187.08 | -50.38 | -- | -- | -1,717.50 | -279.82 | -- | -178.63 | 0.0532 | -- | -18.71 | 51.13 | -18.19 | -- | 22.97 | -- |
| Spexis AG | 0.00 | 1.80m | 20.46m | -- | 0.4006 | 0.7716 | 13.45 | -- | 1.06 | 1.06 | 0.00 | 0.5521 | 0.00 | -- | -- | -- | 5.45 | -- | 9.20 | -- | -- | -- | -- | -- | -- | 0.8156 | 0.1894 | -- | -100.00 | -- | 73.61 | -- | -- | -- |
| Newron Pharmaceuticals SpA | 5.83m | -14.24m | 24.07m | 25.00 | -- | -- | -- | 4.13 | -0.7981 | -0.7981 | 0.3265 | -0.2892 | 0.1419 | -- | 3.50 | 233,049.90 | -34.70 | -25.64 | -38.05 | -28.17 | 98.18 | 86.47 | -244.45 | -216.08 | -- | -3.33 | 1.13 | -- | 9.59 | 4.00 | 29.04 | -- | -22.60 | -- |
| Santhera Pharmaceuticals Holding AG | 163.00k | -64.73m | 38.48m | 39.00 | -- | -- | -- | 236.10 | -1.28 | -1.28 | 0.0032 | -0.2553 | 0.002 | 11.11 | 0.087 | 4,179.49 | -80.91 | -48.15 | -168.64 | -60.86 | -2,115.34 | 80.16 | -39,712.27 | -172.87 | 0.372 | -82.93 | 1.52 | -- | -110.63 | -- | 17.93 | -- | -47.47 | -- |
| Kuros Biosciences AG | 15.16m | -11.14m | 61.42m | 64.00 | -- | 0.7526 | -- | 4.05 | -0.3369 | -0.3369 | 0.4562 | 2.23 | 0.1668 | 2.00 | 3.33 | 261,293.10 | -12.26 | -13.87 | -13.53 | -14.69 | 75.45 | -- | -73.52 | -269.99 | 2.25 | -2.99 | 0.0258 | -- | 242.04 | 67.08 | 34.54 | -- | 49.55 | -- |
| Wockhardt Bio AG | 313.13m | -42.44m | 82.41m | -- | -- | 0.2795 | -- | 0.2632 | -0.7606 | -0.7606 | 6.03 | 5.68 | 0.4792 | 1.80 | 2.50 | -- | -6.50 | -0.7439 | -8.19 | -1.25 | 51.44 | 52.97 | -13.55 | -1.62 | 3.90 | -3.45 | 0.5092 | -- | 12.15 | -2.14 | -107.96 | -- | -8.03 | -- |
| Evolva Holding SA | 11.64m | -44.75m | 85.71m | 62.00 | -- | 0.7547 | -- | 7.37 | -0.0474 | -0.0474 | 0.0124 | 0.1039 | 0.0785 | 1.13 | 2.35 | 171,127.90 | -30.20 | -16.27 | -34.83 | -17.43 | -48.26 | -4.44 | -384.55 | -359.29 | 0.8091 | -- | 0.0974 | -- | 30.99 | 0.6225 | -38.15 | -- | -18.76 | -- |
| RELIEF THERAPEUTICS Holding SA | 7.87m | -46.53m | 133.19m | 55.00 | -- | 0.7559 | -- | 16.93 | -0.0116 | -0.0116 | 0.002 | 0.0385 | 0.0392 | 6.09 | 4.64 | 143,018.20 | -23.16 | -17.42 | -25.24 | -18.92 | 81.96 | -- | -591.50 | -1,372.00 | 2.78 | -51.30 | 0.0247 | -- | -- | 194.47 | -343.34 | -- | 316.02 | -- |
| Xlife Sciences AG | 863.90k | 48.92m | 166.44m | 19.00 | 5.64 | 0.791 | 3.08 | 192.66 | 5.59 | 5.59 | 0.1309 | 39.82 | 0.0026 | -- | 2.32 | 45,468.42 | 13.92 | -- | 16.67 | -- | 38.79 | -- | 5,327.34 | -- | -- | -0.6138 | 0.1615 | -- | 103.14 | -- | 148.91 | -- | -- | -- |
| Molecular Partners AG | 188.71m | 117.37m | 221.49m | 164.00 | 1.75 | 0.7953 | 1.85 | 1.17 | 3.52 | 3.52 | 5.76 | 7.73 | 0.8249 | -- | 51.62 | 1,157,718.00 | 51.31 | -29.24 | 58.86 | -37.44 | -- | 95.94 | 62.20 | -322.54 | -- | -- | 0.0201 | -- | 4.39 | -15.79 | -1.63 | -- | 3.57 | -- |
Data as of Dec 01 2022. Currency figures normalised to Kuros Biosciences AG's reporting currency: Swiss Franc CHF
17.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Credit Suisse Asset Management (Schweiz) AGas of 31 Dec 2021 | 3.28m | 8.97% |
| Banque Pictet & Cie SAas of 31 Dec 2021 | 1.39m | 3.81% |
| Apo Asset Management GmbHas of 31 Oct 2022 | 1.16m | 3.18% |
| UBS Asset Management Switzerland AGas of 01 Nov 2022 | 196.94k | 0.54% |
| Schroder Investment Management (Switzerland) AGas of 30 Nov 2018 | 123.81k | 0.34% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2020 | 70.55k | 0.19% |
| Migros Bank AGas of 30 Jun 2021 | 37.13k | 0.10% |
| BlackRock Asset Management Schweiz AGas of 03 Nov 2022 | 23.25k | 0.06% |
| Lombard Odier Asset Management (Switzerland) SAas of 31 Aug 2022 | 16.90k | 0.05% |
| Equinor Asset Management ASAas of 30 Jun 2022 | 13.75k | 0.04% |
More ▼
Data from 31 Dec 2021 - 31 Oct 2022Source: FactSet Research Systems Inc.
